E/C/F / tenofovir alafenamide was non-inferior to E/C/F / tenofovir disoproxil fumarate , with @ ( @ % ) of @ patients in the tenofovir alafenamide group and @ ( @ % ) of @ patients in the tenofovir disoproxil fumarate group having plasma HIV-@ RNA less than @ copies per mL ( adjusted difference @ % , @ % CI -@ to @ ) .